Lipoprotein(a)
Lipoprotein(a), often abbreviated as Lp(a) or LPA, is a specialized subclass of lipoprotein. It has garnered significant attention in the medical and scientific community due to its established role as a risk factor for atherosclerotic diseases, which include coronary heart disease and stroke. First discovered in 1963 by Kåre Berg, its significance has been underscored by various genetic and epidemiologic studies.
Structure[edit | edit source]
Lp(a) comprises a core low-density lipoprotein (LDL) particle bound to the distinctive apolipoprotein(a) (apo(a)) protein. This unique structural configuration distinguishes Lp(a) from other lipoproteins in the bloodstream.
Populations[edit | edit source]
The concentration of Lp(a) varies significantly among individuals and is influenced by both genetic and environmental factors. Some populations may naturally have higher or lower levels of Lp(a) based on genetic predispositions.
Function and Pathology[edit | edit source]
While the exact physiological role of Lp(a) is still under investigation, it's widely acknowledged for its pathological role, especially in relation to cardiovascular health. Lp(a) contributes to the formation of plaques in the arteries, leading to atherosclerosis. This can cause reduced blood flow and increase the risk of heart attacks and strokes.
Catabolism and Clearance[edit | edit source]
Lp(a) is primarily cleared from the bloodstream by the liver. The exact pathways and mechanisms of how the liver processes and eliminates Lp(a) are still areas of active research.
Lipoprotein(a) and Disease[edit | edit source]
Beyond atherosclerosis, elevated Lp(a) levels have been associated with various other diseases. This includes:
- Coronary heart disease
- Ischemic stroke
- Peripheral artery disease
- Aortic valve stenosis
Diagnostic Testing[edit | edit source]
Measuring Lp(a) levels can provide valuable insights into an individual's risk for certain cardiovascular diseases. Diagnostic tests usually involve blood samples and specialized assays.
Treatment[edit | edit source]
While there are no specific treatments designed to lower Lp(a) levels, strategies typically involve managing overall cardiovascular risk. This can include:
- Statin therapy
- Lifestyle changes such as dietary modifications and exercise
- Emerging therapies targeting Lp(a) specifically
Interactions[edit | edit source]
Lp(a) may interact with various other proteins and molecules within the bloodstream. These interactions can influence its physiological and pathological roles.
See Also[edit | edit source]
| Lipoprotein(a) Resources | ||
|---|---|---|
|
| |
PDB gallery | |
|---|---|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
